Skip to content

PRF Versus Emdogain for Class II Furcation Defects of Mandibular Molars

Comparative Evaluation of the Regenerative Potential of Platelet- Rich Fibrin (PRF) and Emdogain® in the Surgical Treatment of Class II Furcation Defects of Mandibular Molars

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07841301
Enrollment
21
Registered
2026-09-25
Start date
2021-12-02
Completion date
2023-05-29
Last updated
2026-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peridontal Disease, Furcation Defects

Keywords

Periodontitis, Class II furcation defects, Platelet-rich fibrin, Emdogain, Periodontal regeneration, Mandibular molars

Brief summary

This study evaluated the regenerative potential of platelet-rich fibrin (PRF) compared with enamel matrix derivative (Emdogain®) in the surgical treatment of Class II (F2) furcation defects of mandibular molars. Twenty-one systemically healthy patients with a total of 30 mandibular molars presenting with buccal Class II furcation defects were included. The furcation defects were treated surgically with either PRF or Emdogain®. Clinical parameters, including periodontal probing depth, clinical attachment level, bleeding on probing, and furcation involvement, were assessed before treatment and during follow-up. Clinical and radiographic measurements of the furcation defects were also performed. The main follow-up evaluation was conducted 6 months after surgery. The study compared the clinical and radiographic outcomes of PRF and Emdogain® in the treatment of mandibular molars with Class II furcation defects.

Interventions

BIOLOGICALPlatelet rich fibrin

Surgical treatment of a buccal Class II furcation defect was performed under local anesthesia. Following flap elevation, complete instrumentation of the root surfaces and furcation defect was performed using hand and powered instruments (scaling and root planing). Horizontal and vertical furcation involvement were measured. For PRF preparation, peripheral venous blood was collected into two vacuum tubes using a closed butterfly system. The tubes were centrifuged using a PRF DUO centrifuge. PRF from one tube was used to fill the furcation defect, while PRF from the second tube was compressed to form a membrane covering the furcation entrance. The flap was coronally positioned and secured with sling and interrupted interdental sutures using resorbable 6-0 sutures.

BIOLOGICALEmdogain

Surgical treatment of a buccal Class II furcation defect was performed under local anesthesia. Following flap elevation, complete instrumentation of the root surfaces and furcation defect was performed using hand and powered instruments (scaling and root planing). Horizontal and vertical furcation involvement were measured. The exposed root surfaces were conditioned with 24% EDTA gel (PrefGel®, Straumann; pH 6.7) for 2 minutes, followed by thorough irrigation with sterile saline. Enamel matrix derivative (Emdogain®) was then immediately applied, starting from the most distant part of the furcation defect and covering the entire exposed root surface. The flap was coronally positioned and secured with sling and interrupted interdental sutures using resorbable 6-0 sutures.

Sponsors

Medical University of Sofia
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Systemically healthy individuals * Stage III or Stage IV periodontitis * without allergies.

Exclusion criteria

* Smoking * Inadequate plaque control * Systemic diseases that may compromise periodontal therapy, including diabetes, immunodeficiency, or viral diseases. * Immunosuppressive therapy. * Treatment with bisphosphonates. * Treatment with anticoagulants. * Treatment with antiplatelet agents. * Thrombocytopenia. * Hypofibrinogenemia. * Hemophilia. * Other coagulation disorders. * Pregnancy. * Breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
Change in Horizontal Furcation Probing DepthBaseline to 6 months after surgeryChange in the horizontal probing depth of the furcation defect, measured at the furcation entrance before surgery and 6 months after surgery. The measurement was used to assess the horizontal component of furcation involvement and the clinical response to treatment.

Secondary

MeasureTime frameDescription
Change in Probing Pocket DepthBaseline to 6 months after surgeryChange in periodontal probing depth at the treated furcation site, measured from m.gingivalis to the bottom of the pocket.
Change in Clinical Attachment LevelBaseline to 6 months after surgeryChange in clinical attachment level at the treated furcation site, measured from cementoenamel junction to the bottom of the pocket.
Change in Vertical Bone LossBaseline to 6 months after surgeryChange in vertical bone loss associated with the furcation defect, measured on three-dimensional imaging.
Change in Horizontal Bone Loss.Baseline to 6 months after surgeryChange in horizontal bone loss associated with the furcation defect, measured on three-dimensional imaging.

Countries

Bulgaria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 26, 2026